Abstract P126 Table 1

Spirometric and symptomatic variables in symptomatic patients with COPD (baseline E-RS ≥10)

	Day 1			Week 6

Change from baseline in normalised FEV₁ vs placebo, mL	Aclidinium 400 µg	Tiotropium 18 µg	Aclidinium vs tiotropium	Aclidinium 400 µg	Tiotropium 18 µg	Aclidinium vs tiotropium

FEV₁ AUC_–24/24h	150*	87*	63†	140**	106*	34
FEV₁AUC_12–24/12h (night-time)	157**	67*	90†	153**	90**	63†
FEV₁AUC_–12(day time)	147**	112**	35	126*	123*	3
Morning pre-dose (trough) FEV₁	136**	68*	68†	137*	70*	65†
E-RS Total Score over 6 weeks	-	-	-	-2.15*	-0.98	-1.17†
^a Early morning symptom severity over 6 weeks (% reduction)	-	-	-	-0.25* (-9.54%)	-0.11 (-4.33%)	-0.14^† (-5.21%)
^b Night-time symptom severity over 6 weeks (% reduction)	-	-	-	-0.23* (-10.31%)	-0.09 (-4.23%)	-0.14 ^† (-6.09%)

↵*p < 0.05 vs placebo; **p ≤ 0.0001 vs placebo; ^†p < 0.05 vs tiotropium.
↵^aLeast squares mean change from baseline in the severity of early morning symptoms over 6 weeks: 1 = No symptoms, 2 = Mild, 3 = Moderate, 4 = Severe, 5 = Very severe.
↵^bChange from baseline in the severity of night-time symptoms over 6 weeks: 1 = No symptoms, 2 = Mild, 3 = Moderate, 4 = Severe, 5 = Very severe.
AUC, area under the curve; COPD, chronic obstructive pulmonary disease; E-RS, EXAcerbations of Chronic pulmonary disease Tool-Respiratory Symptoms; FEV₁, forced expiratory volume in 1 s.